• World
    • Africa
    • Asia Pacific
    • Central & South Asia
    • Europe
    • Latin America & Caribbean
    • Middle East & North Africa
    • North America
  • Coronavirus
  • Politics
    • US Election
    • US politics
    • Donald Trump
    • Brexit
    • European Union
    • India
    • Arab world
  • Economics
    • Finance
    • Eurozone
    • International Trade
  • Business
    • Entrepreneurship
    • Startups
    • Technology
  • Culture
    • Entertainment
    • Music
    • Film
    • Books
    • Travel
  • Environment
    • Climate change
    • Smart cities
    • Green Economy
  • Global Change
    • Education
    • Refugee Crisis
    • International Aid
    • Human Rights
  • International Security
    • ISIS
    • War on Terror
    • North Korea
    • Nuclear Weapons
  • Science
    • Health
  • 360 °
  • The Interview
  • In-Depth
  • Insight
  • Quick Read
  • Video
  • Podcasts
  • Interactive
  • My Voice
  • About
  • FO Store
Sections
  • World
  • Coronavirus
  • US Election
  • Politics
  • Economics
  • Business
  • Culture
  • Sign Up
  • Login
  • Publish

Make Sense of the world

Unique insight from 2,000+ contributors in 80+ Countries

Close

India’s Tactical Victory on HCQ Misses the Bigger Picture

Based on popular opinion across the country, India has already rescued the world by supplying the miracle drug against COVID-19.
By Mauktik Kulkarni • Apr 27, 2020
Donald Trump hydroxychloroquine COVID-19, Trump HCQ for coronavirus, what is HCQ, HCQ Covid-19 trials, India HCQ news, Narendra Modi news, India generic drugs, India HCQ exports, India coronavirus news, Mauktik Kulkarni

© Vivi-o / Shutterstock

Amid the debate surrounding COVID-19, the rhetoric around hydroxychloroquine (HCQ) in the United States and India is the best example of the populism of our times. Earlier on in the pandemic, anecdotal evidence from France led US President Donald Trump to proclaim that all the patients should try HCQ against the coronavirus. In a matter of days, Trump had called up India’s Prime Minister Narendra Modi, a large shipment of HCQ was on the way from India to the US, and both the leaders were congratulating each other for a job well done.

However, results from a study (not yet peer-reviewed) funded by the National Institutes of Health in the United States, made public last week, indicate that the drug has no benefit for COVID-19 patients and might in fact increase the mortality rate. More data and rigorous reviews are needed to solidify these claims but, based on popular opinion across the country, India has already rescued the world by supplying the miracle drug.

Since the 2014 national election campaign in India, misplaced jingoism, fake news and brainwashing the electorate through social media have become the norm. India will pay dearly for the misinformation the ruling Bharatiya Janata Party’s WhatsApp warriors spread about minorities and the country’s fiscal health, and the willful ignorance of facts by voters. When top executives of start-ups — poster boys of the new, innovative Indian economy — begin chest-thumping about HCQ, it is worth examining the global pharmaceutical landscape, India’s place in it and the peculiar circumstances that have brought this age-old drug back into the spotlight.

A Long Way to Go

HCQ is a synthetic and enhanced version of quinine, a treatment for malaria known since the 1600s. India did not play any significant role in identifying the tree, biochemically isolating the active ingredient from the bark, inventing its synthetic version or patenting the first HCQ tablets. These breakthroughs happened in colonial-era Europe and the United States.

While India has a rich tradition of Ayurveda-based alternative medicine, the mechanism of action and efficacy of most such treatments remain unknown. Active ingredients in centuries-old remedies like turmeric and neem are being established, and they could become effective treatments for various ailments. Beyond that, while Indians have made a mark in the Western health-care arena, India’s contribution to modern medicine remains negligible. With increased investments in basic science and health-care start-ups, India might lead the world in drug development in a few decades. There is a long way to go.

Embed from Getty Images

On average, Western pharma entities collectively spend an estimated $1 billion to $2.6 billion to develop a new drug, the cost increasing by 8.5% annually. That includes molecular-level research, biochemical stability and manufacturing studies, risk and efficacy testing on animals, and the three rounds of human testing — to recommend dosage — mandated by the Food and Drug Administration (FDA). The majority of human tests fail, which explains the staggering cost.

When a new drug is launched, pharma companies carry 20-year patents for the process and the product, ensuring that no other company can manufacture the drug. It allows them to recoup their investments. Once the patents expire, others can manufacture cheaper generic versions. Until 1999, Indian laws allowed process patents but had no product patents. Within months of Western countries launching new medicines, Indian companies could chemically analyze them, find easier or cheaper ways to manufacture them and sell them to poorer countries for pennies to the dollar.

While Western companies were earning through huge profit margins in countries with product patents, Indian counterparts were earning through huge volumes in the developing world. These worlds collided during the 1990s HIV-AIDS crisis. With higher literacy, effective public messaging and purchasing power, the West rapidly controlled the spread of the disease. When it started spreading in developing countries, particularly in Africa, Indian companies started hurting the bottom line of their Western rivals by providing cheaper alternatives. In the ever-evolving global patent regime, there are several ethical gray areas.

Pharma giants often make minor changes in their drugs or their delivery mechanism to file new patents, a practice known as “evergreening” that the Indian courts are successfully fighting against. On the other hand, manufacturers will sometimes relax patent protection rules in critical circumstances, like Medtronic has done with ventilator designs to help others manufacture cheaper versions during the ongoing coronavirus pandemic.

Back in the 1990s, a global compromise was reached. While cheaper Indian drugs were used — most notably by Bill Clinton’s administration — to fight HIV in Africa, India was forced to enact product patents in the pharma industry. Since then, India has kept manufacturing generics but has developed very few, if any, new drugs. With a GDP of $2.5 trillion, per-capita income of around $2,000, excessive bureaucracy, paltry investment in basic sciences, lack of risk appetite among pharma and venture capital firms, and non-availability of biotech talent, India is not conducive for such capital-intensive efforts.

Tactical Victories

That brings us to the HCQ saga. The drug has been off-patent for decades. While it is effective for the treatment of rheumatoid arthritis and lupus, its primary target —  malaria  — was eliminated in the developed world decades ago. The West stopped manufacturing large quantities of HCQ because margins and volumes were low. India still manufactures it in large quantities because it is still battling this old enemy.

Donald Trump arguing “What do you have to lose?” to promote HCQ as a COVID-19 therapy flies in the face of doctors’ principle of “First, do no harm.” It has well-documented, occasionally severe, cardiac side effects. Although not backed by rigorous testing, its prophylactic use by frontline health-care workers might protect them from infections. This prompted New York’s Governor Andrew Cuomo to place a large order with Indian manufacturers.

logo

Make Sense of the World

Unique insight from 2,000+ contributors in 80+ Countries

Make Sense of the World
Unique insights from 2000+ contributors in 80+ countries

By then, the United States had already halted pharmaceutical exports, and the large US order prompted India to follow suit. When Trump dialed Modi to ask him to lift India’s export ban and process American HCQ orders, India had precious little leverage. (In a Freudian slip, Trump said as much in one of his press briefings.) India reversed the export ban and processed the orders from the US and several other countries. Indian diplomats have squeezed out a tweet from Trump congratulating Modi and secured an extension of expiring H1B visas for Indian expats. They seem to be working behind the scenes for a dollar-swap line to stop the slide of the underperforming rupee.

These are small but good tactical victories for India, which routinely punches above its weight in international affairs. India’s FDA-approved facilities to mass-produce HCQ and the ability to ramp it up on short notice are laudable, but after the latest clinical trials demonstrating that it does not benefit COVID-19 patients, even Trump has backtracked on his earlier claims. Saying that India is rescuing the United States, let alone the world, by supplying HCQ trivializes the issue. India is still recovering from colonial-era socioeconomic setbacks. It needs time to invest in education, world-class research and development infrastructure, and build a scientific culture.

However, that debate requires humility, which is in short supply in today’s populist and nationalist India. In his response to Trump, Modi has already tweeted that “India shall do everything possible to help humanity’s fight against Covid-19,” while his WhatsApp warriors have done their job of projecting India as the savior of the world.

The views expressed in this article are the author’s own and do not necessarily reflect Fair Observer’s editorial policy.

Share Story
Categories360° Analysis, American News, Business, Central & South Asia, Coronavirus, Global inequality news, Health, Indian politics news, Inequality news, Insight, International Trade, North America, Politics, Science TagsDonald Trump hydroxychloroquine COVID-19, HCQ Covid-19 trials, India coronavirus news, India generic drugs, India HCQ exports, India HCQ news, Mauktik Kulkarni, Narendra Modi news, Trump HCQ for coronavirus, what is HCQ
Join our network of more than 2,000 contributors to publish your perspective, share your story and shape the global conversation. Become a Fair Observer and help us make sense of the world.

READ MORE IN THIS 360° SERIES

In Sierra Leone, COVID-19 Could Make Maternal Mortality Worse
By Emma Minor • Jul 06, 2020
Herd Immunity May Be Our Best Hope
By Daniel Wagner & Mark Eckley • Jul 06, 2020
The EU Should Collect Health Data Centrally
By Susan Bergner & Isabell Kump • Jun 29, 2020
How Will COVID-19 Change Our World?
By Atul Singh • Jun 26, 2020
How Mismanaging a Pandemic Can Cost Countries Their Soft Power
By Valerio Alfonso Bruno • Jun 18, 2020
COVID-19 Contact Tracing: A Wolf in Sheep’s Clothing?
By Claire Downing • Jun 10, 2020
If the Pandemic Is a “War,” Then India Needs to Spend More
By Bobby Ramakant, Sandeep Pandey & Shobha Shukla • Jun 08, 2020
What Is the Key to Tunisia Successfully Beating COVID-19?
By Bill Law • Jun 08, 2020
The Humanitarian Disaster Before Us: COVID-19 in Somalia
By Arden Bentley • Jun 06, 2020
East Africa Faces a Cascade of Crises
By Bettina Rudloff & Annette Weber • Jun 04, 2020
The Swiss People’s Party Versus COVID-19
By Hans-Georg Betz • Jun 03, 2020
The 2020 Pandemic Election
By Saurabh Jha • May 29, 2020
COVID-19 Casts a Shadow Over Swedish Exceptionalism
By Mette Wiggen • May 21, 2020
Has COVID-19 Launched a New Era of Deadly Pandemics?
By I.P. Singh & Atul Singh • May 19, 2020
COVID-19 Arrives in Refugee Camps
By Phil Cole • May 18, 2020
The Worst President at the Worst Time
By Larry Beck • May 14, 2020
South Korea Faces Challenges in a Post-Coronavirus World
By Thomas Kalinowski • May 13, 2020
Debunking Trump’s China Nonsense
By John Feffer • May 08, 2020
Global Health Policy Is World Politics
By Susan Bergner, Maike Voss & Nadine Godehardt • May 07, 2020
Will We Ever Know the True Origin of COVID-19?
By Daniel Wagner • May 06, 2020
COVID-19: What Indonesia Can Learn From South Korea and Taiwan
By Luthfi Dhofier • May 05, 2020
Brazil Struggles to Find a Unified Approach to the Coronavirus Pandemic
By Thiago Alves Ferreira & Stephanie Fillion • May 05, 2020
Narendra Modi Is Fighting COVID-19 With Little Logic
By Satish Jha • May 01, 2020
What You Need to Know About the COVID-19 Crisis in the US
By Sunil Asnani & Kshitij Bhatia • Apr 30, 2020
History Will Judge Britain’s COVID-19 Response
By Rupert Hodder • Apr 30, 2020
China’s Uncertain Recovery From COVID-19
By Maa Zhi Hong • Apr 29, 2020
Rohingya Refugee Camps Are the Next Frontline in COVID-19 Fight
By Daniel Sullivan • Apr 28, 2020
Brazil Is Heading Into a Perfect Storm
By Lenin Cavalcanti Guerra • Apr 28, 2020
Will COVID-19 Alter the Global Order?
By Joel Blankenship • Apr 27, 2020
South Korea Shows the Way Forward for Post-Pandemic Recovery
By John Feffer • Apr 24, 2020
Why Maximum Pressure on Venezuela Is the Only Way Out
By Leonardo Vivas • Apr 22, 2020
Can the WHO Restore Credibility After Its Handling of the COVID-19 Pandemic?
By Hans-Georg Betz • Apr 22, 2020
For Cybercriminals, a Global Pandemic Presents an Opportunity
By Beau Peters • Apr 17, 2020
Playing Catch-Up With the Next Pandemic
By John Feffer • Apr 17, 2020
The Politics Behind the Coronavirus in Brazil
By Helder Ferreira do Vale • Apr 15, 2020
Remembering the Easter Sunday Victims in the Shadow of COVID-19
By Amjad Saleem • Apr 14, 2020
China's Mask Diplomacy Won't Change the World Order
By Brennan Kau • Apr 09, 2020
How the US Government Failed to Prepare for a Pandemic
By Daniel Wagner • Apr 09, 2020
As President, Donald Trump Has a Duty
By Gary Grappo • Apr 08, 2020
Should We All Have Been Wearing Masks From the Start?
By Hans-Georg Betz • Apr 07, 2020
In Tajikistan, It’s Someone Else’s Virus
By Andrea Schmitz • Apr 06, 2020
Why Are Mexico and Brazil So Slow in Reacting to COVID-19?
By Lenin Cavalcanti Guerra • Apr 01, 2020
Are We Wrong About COVID-19 Death Rates?
By Daniel Wagner • Mar 31, 2020
One Antidote to Coronavirus: More Multilateralism
By Gary Grappo • Mar 30, 2020
Saudi Arabia’s Wars on Three Fronts
By Bill Law • Mar 30, 2020
The Politics of the Coronavirus
By John Feffer • Mar 27, 2020
What the Coronavirus Says About Us
By John Feffer • Mar 24, 2020
Why It’s Taking Britain So Long to Tackle COVID-19
By Rupert Hodder • Mar 23, 2020
COVID-19: What Italy and the US Are Doing Wrong
By Valerio Alfonso Bruno • Mar 10, 2020
The British Government Is About to Fail on Coronavirus
By Rupert Hodder • Mar 09, 2020
Coronavirus Outbreak Puts the World’s Governments on Notice
By Daniel Wagner • Mar 03, 2020
Coronavirus Outbreak Exacerbates Italy’s Political Divisions
By Valerio Alfonso Bruno • Feb 27, 2020
China’s Influence Dampens International Response to Coronavirus Outbreak
By Daniel Wagner • Feb 24, 2020
How Effective Is China’s Response to the Coronavirus Outbreak?
By Maa Zhi Hong • Feb 04, 2020

Post navigation

Previous PostPrevious Will COVID-19 Alter the Global Order?
Next PostNext Does COVID-19 Kill People Who Tend to Hold Their Breath?
Subscribe
Register for $9.99 per month and become a member today.
Publish
Join our community of more than 2,500 contributors to publish your perspective, share your narrative and shape the global discourse.
Donate
We bring you perspectives from around the world. Help us to inform and educate. Your donation is tax-deductible.

Explore

  • About
  • Authors
  • FO Store
  • FAQs
  • Republish
  • Privacy Policy
  • Terms of Use
  • Contact

Regions

  • Africa
  • Asia Pacific
  • Central & South Asia
  • Europe
  • Latin America & Caribbean
  • Middle East & North Africa
  • North America

Topics

  • Politics
  • Economics
  • Business
  • Culture
  • Environment
  • Global Change
  • International Security
  • Science

Sections

  • 360°
  • The Interview
  • In-Depth
  • Insight
  • Quick Read
  • Video
  • Podcasts
  • Interactive
  • My Voice

Daily Dispatch


© Fair Observer All rights reserved
We Need Your Consent
We use cookies to give you the best possible experience. Learn more about how we use cookies or edit your cookie preferences. Privacy Policy. My Options I Accept
Privacy & Cookies Policy

Edit Cookie Preferences

The Fair Observer website uses digital cookies so it can collect statistics on how many visitors come to the site, what content is viewed and for how long, and the general location of the computer network of the visitor. These statistics are collected and processed using the Google Analytics service. Fair Observer uses these aggregate statistics from website visits to help improve the content of the website and to provide regular reports to our current and future donors and funding organizations. The type of digital cookie information collected during your visit and any derived data cannot be used or combined with other information to personally identify you. Fair Observer does not use personal data collected from its website for advertising purposes or to market to you.

As a convenience to you, Fair Observer provides buttons that link to popular social media sites, called social sharing buttons, to help you share Fair Observer content and your comments and opinions about it on these social media sites. These social sharing buttons are provided by and are part of these social media sites. They may collect and use personal data as described in their respective policies. Fair Observer does not receive personal data from your use of these social sharing buttons. It is not necessary that you use these buttons to read Fair Observer content or to share on social media.

 
Necessary
Always Enabled

These cookies essential for the website to function.

Analytics

These cookies track our website’s performance and also help us to continuously improve the experience we provide to you.

Performance
Uncategorized

This cookie consists of the word “yes” to enable us to remember your acceptance of the site cookie notification, and prevents it from displaying to you in future.

Preferences
Save & Accept